ANA – ENA Profile – IgG Autoantibodies at Lahore PCR Lab

ANA – ENA Profile – IgG at Lahore PCR Lab

The Antinuclear Antibody (ANA) and Extractable Nuclear Antigen (ENA) Profile for IgG class antibodies is a sophisticated, comprehensive panel of immunological tests designed to detect and identify specific autoantibodies in the blood. Under normal physiological conditions, the human immune system produces antibodies to defend the body against foreign pathogens such as bacteria, viruses, and toxins. However, in patients suffering from systemic autoimmune rheumatic diseases (SARD), the immune system undergoes a dysregulation, mistakenly producing autoantibodies that target the body’s own cellular components. The ANA – ENA Profile – IgG at Lahore PCR Lab serves as a critical diagnostic tool, enabling clinicians to identify these self-targeting proteins with high precision and sensitivity.

This advanced laboratory evaluation is of paramount clinical importance. It does not merely indicate the presence of general autoimmunity; rather, it systematically dissects the patient’s autoantibody profile by screening for antibodies directed against specific intracellular proteins and nucleic acids. These target antigens, located within the cell nucleus and cytoplasm, include double-stranded DNA (dsDNA), Smith (Sm), Ribonucleoprotein (RNP), Sjögren’s Syndrome A (SSA/Ro), Sjögren’s Syndrome B (SSB/La), Scl-70 (topoisomerase I), and Jo-1. By identifying the exact IgG autoantibodies circulating in a patient’s bloodstream, the medical team can differentiate between various overlapping connective tissue disorders, formulate an accurate prognosis, and establish a highly targeted therapeutic strategy.

At Lahore PCR Lab, located in Lahore, Pakistan, this panel is performed using state-of-the-art immunological methodologies, such as Line Immunoassay (LIA), Enzyme-Linked Immunosorbent Assay (ELISA), or multiplex bead assays. These technologies ensure exceptional analytical specificity and sensitivity, minimizing the risk of false-positive or false-negative results. For patients presenting with vague, multisystemic symptoms like chronic joint pain, persistent fatigue, unexplained skin rashes, or prolonged low-grade fevers, this diagnostic profile offers clarity, helping to pave the way toward timely intervention and improved long-term clinical outcomes.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the utmost accuracy of the ANA – ENA Profile – IgG results, patients must adhere to specific preparation guidelines prior to their blood draw at Lahore PCR Lab:

• Medication Review: Patients must inform their prescribing physician and the laboratory staff of all medications, supplements, and herbal remedies they are currently taking. Immunosuppressive drugs, systemic corticosteroids, and certain biologic therapies can suppress antibody production, potentially leading to false-negative results. Conversely, certain medications can induce drug-induced lupus, altering the autoantibody profile.
• Fasting Requirements: Strictly speaking, fasting is not mandatory for an isolated ANA – ENA Profile – IgG test. However, because this panel is frequently ordered alongside other metabolic or lipid profiles, a 10 to 12-hour fast may be recommended by your physician. If no other tests are scheduled, a light meal prior to the test is acceptable.
• Hydration: Adequate hydration is highly recommended. Drinking plenty of water before the procedure increases blood volume, making the veins more visible and accessible, which facilitates a smoother venipuncture process.
• Clothing: Patients should wear comfortable clothing with loose sleeves that can be easily rolled up above the elbow to allow unobstructed access to the venipuncture site.

During the Procedure

The collection of the blood sample for the ANA – ENA Profile – IgG at Lahore PCR Lab is a routine, safe, and highly standardized procedure performed by experienced phlebotomists:

• Patient Positioning: The patient is seated comfortably in a specialized phlebotomy chair. The phlebotomist will ask the patient to extend their arm, resting it on a supportive surface.
• Site Selection and Sanitization: The phlebotomist inspects the antecubital fossa (the crease of the elbow) to locate a suitable, robust vein. Once selected, the area is thoroughly cleansed with an antiseptic solution (typically 70% isopropyl alcohol) to prevent any microbial contamination of the sample or the puncture site.
• Tourniquet Application: A sterile elastic tourniquet is applied around the upper arm. This temporarily restricts venous blood flow, causing the veins below the band to swell and become more prominent.
• Venipuncture: A sterile, single-use needle attached to a vacuum collection tube (typically a serum separator tube with a gold or red top) is gently inserted into the vein. The patient may feel a brief, minor pinch or prick.
• Sample Collection: As the blood flows into the tube, the tourniquet is released to restore normal circulation. Once the required volume of blood is collected, the needle is carefully withdrawn.
• Post-Puncture Care: Immediate, gentle pressure is applied to the puncture site using a sterile cotton ball or gauze pad to promote hemostasis. A small adhesive bandage is then applied to keep the site clean.
• Safety and Duration: The entire venipuncture process is completed in less than five minutes. It carries minimal risk, with mild bruising or slight localized soreness being the only common, self-limiting side effects.

When is a ANA – ENA Profile – IgG Performed?

Evaluation of Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus is a chronic, multisystem autoimmune disease characterized by widespread inflammation and tissue damage. Physicians frequently request the ANA – ENA Profile – IgG when a patient presents with classic clinical hallmarks of SLE, such as a malar (butterfly) rash across the cheeks and nose, photosensitivity, non-erosive arthritis, alopecia, oral ulcers, and unexplained nephritis. The presence of specific IgG autoantibodies, particularly anti-dsDNA and anti-Smith (anti-Sm), is highly specific for SLE and plays a pivotal role in confirming the diagnosis under established rheumatology classification criteria.

Diagnosis of Sjögren’s Syndrome

Sjögren’s Syndrome is an autoimmune disorder primarily targeting the exocrine glands, leading to severe mucosal dryness. Clinicians order this profile for patients complaining of chronic dry eyes (keratoconjunctivitis sicca), dry mouth (xerostomia), bilateral parotid gland enlargement, and systemic joint pain. The ANA – ENA panel specifically evaluates the presence of anti-SSA (Ro) and anti-SSB (La) antibodies. Detecting these IgG autoantibodies is crucial, as they confirm the autoimmune etiology of the patient’s sicca symptoms and help differentiate primary Sjögren’s from secondary forms associated with other connective tissue diseases.

Identification of Mixed Connective Tissue Disease (MCTD)

Mixed Connective Tissue Disease is an overlap syndrome that presents with clinical features common to SLE, systemic sclerosis, and polymyositis. Patients often exhibit Raynaud’s phenomenon (discoloration of fingers in response to cold), swollen hands, joint inflammation, and muscle weakness. The ANA – ENA Profile – IgG is indispensable in this clinical scenario, as the diagnosis of MCTD requires the detection of extremely high titers of anti-U1-Ribonucleoprotein (anti-U1 RNP) antibodies in the absence of other SARD-specific antibodies. This helps clinicians establish a clear diagnostic pathway and initiate appropriate therapy.

Assessment of Systemic Sclerosis (Scleroderma)

Systemic Sclerosis is a rare autoimmune disease characterized by progressive fibrosis of the skin and internal organs, alongside vascular abnormalities. Physicians utilize the ANA – ENA profile when patients present with skin thickening (sclerodactyly), severe Raynaud’s phenomenon, esophageal dysmotility, or unexplained pulmonary hypertension. The panel screens for anti-Scl-70 (anti-topoisomerase I) and anti-centromere antibodies. Identifying these markers not only aids in diagnosing scleroderma but also assists in classifying the disease into diffuse or limited cutaneous subtypes, which carry vastly different prognoses.

Investigation of Inflammatory Myopathies

Idiopathic inflammatory myopathies, including polymyositis and dermatomyositis, are characterized by chronic, progressive muscle weakness and, in some cases, distinctive skin rashes (such as Gottron’s papules or a heliotrope rash). When a patient presents with proximal muscle weakness, elevated muscle enzymes (like creatine kinase), and systemic fatigue, the ANA – ENA Profile – IgG is ordered to detect anti-Jo-1 (histidyl-tRNA synthetase) antibodies. Finding this marker helps confirm an autoimmune myopathy and alerts the clinician to the potential risk of interstitial lung disease, which is highly associated with anti-synthetase syndrome.

What Does a ANA – ENA Profile – IgG Detect?

The ANA – ENA Profile – IgG is designed to detect a wide array of specific autoantibodies and clinical parameters, including:

• Antinuclear Antibodies (ANA) Screen: Detects the presence of general IgG antibodies targeting nuclear antigens, reported as a titer and a specific cellular pattern (e.g., homogeneous, speckled, nucleolar, or centromere).
• Anti-double-stranded DNA (anti-dsDNA): Highly specific marker for Systemic Lupus Erythematosus (SLE), strongly correlated with lupus nephritis and disease activity.
• Anti-Smith (anti-Sm) Antibodies: An extremely specific diagnostic marker for SLE, rarely found in other conditions.
• Anti-U1 Ribonucleoprotein (anti-U1 RNP): The diagnostic hallmark of Mixed Connective Tissue Disease (MCTD) when present in high titers.
• Anti-SSA (Ro) 60 kDa Antibodies: Associated with Sjögren’s syndrome, SLE, and subacute cutaneous lupus.
• Anti-SSA (Ro) 52 kDa Antibodies: Frequently detected in Sjögren’s syndrome, inflammatory myopathies, and neonatal lupus.
• Anti-SSB (La) Antibodies: Strongly associated with Sjögren’s syndrome, almost always occurring in conjunction with anti-SSA antibodies.
• Anti-Scl-70 (Topoisomerase I): Highly specific marker for diffuse cutaneous systemic sclerosis, indicating a higher risk of pulmonary fibrosis.
• Anti-Centromere Antibodies (ACA): Associated with limited cutaneous systemic sclerosis (formerly CREST syndrome) and a lower risk of severe internal organ involvement.
• Anti-Jo-1 (Histidyl-tRNA Synthetase): The primary marker for anti-synthetase syndrome, indicating polymyositis, dermatomyositis, and interstitial lung disease.
• Anti-Histone Antibodies: Frequently associated with drug-induced lupus erythematosus.
• Anti-Ribosomal P Protein: Highly specific marker for SLE, often associated with neuropsychiatric lupus manifestations.
• Anti-Nucleosome Antibodies: Important marker for SLE, especially in patients who are negative for anti-dsDNA.
• Anti-PM-Scl Antibodies: Associated with polymyositis and systemic sclerosis overlap syndrome.
• Anti-Mi-2 Antibodies: Highly specific marker for classic dermatomyositis, generally associated with a favorable response to therapy.
• Quantitative IgG Autoantibody Levels: Provides specific concentration values for each ENA antigen to assist in clinical correlation.
• Immunofluorescence Patterns: Visual representation of how antibodies bind to HEp-2 cells, guiding the initial diagnostic direction.
• Negative Autoantibody Profile: Helps rule out active systemic rheumatic diseases with high negative predictive value.
• Overlapping Autoantibody Profiles: Identifies patients with overlap syndromes who exhibit markers for multiple distinct autoimmune diseases.
• Risk of Congenital Heart Block: Identifies anti-SSA/SSB positive pregnant patients whose fetuses require monitoring for congenital heart block.
• Baseline Immunological Status: Establishes a baseline profile prior to commencing immunosuppressive or biological therapies.

Turnaround Time and Report Access at Lahore PCR Lab

At Lahore PCR Lab, the processing of the ANA – ENA Profile – IgG is conducted with the highest level of clinical diligence. Because this panel utilizes advanced multiplex assays and line immunoassays to evaluate multiple distinct autoantibodies simultaneously, the testing process requires meticulous calibration, incubation, and quality control checks. This ensures that every result delivered is highly accurate and clinically reliable.

The typical turnaround time for the ANA – ENA Profile – IgG at Lahore PCR Lab is clearly communicated to patients at the time of sample collection. Once the analysis is completed, the final diagnostic report is thoroughly reviewed and signed off by a qualified consultant pathologist or clinical immunologist. Patients can conveniently access their reports online through the official Lahore PCR Lab web portal, or receive them via SMS and email notifications. Physical copies of the reports can also be collected directly from the main diagnostic center in Lahore.

ANA – ENA Profile – IgG Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
ANA Screen (IgG)	Negative (Titer < 1:80)	Positive (Titer ≥ 1:80 with Speckled, Homogeneous, or Nucleolar patterns)
Anti-dsDNA	Negative (< 10 IU/mL)	Positive (≥ 10 IU/mL), highly suggestive of SLE and active lupus nephritis
Anti-Smith (Sm)	Negative	Positive, highly specific diagnostic indicator for SLE
Anti-U1 RNP	Negative	Positive, diagnostic marker for Mixed Connective Tissue Disease (MCTD)
Anti-SSA (Ro)	Negative	Positive, indicative of Sjögren’s Syndrome, SLE, or neonatal lupus risk
Anti-SSB (La)	Negative	Positive, strongly associated with Sjögren’s Syndrome and SLE
Anti-Scl-70	Negative	Positive, associated with diffuse cutaneous systemic sclerosis (Scleroderma)
Anti-Jo-1	Negative	Positive, associated with polymyositis, dermatomyositis, and lung disease

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Lahore PCR Lab for ANA – ENA Profile – IgG?

• Experienced Healthcare Professionals: Our laboratory is staffed by highly trained pathologists, immunologists, and technologists specializing in autoimmune diagnostics.
• Patient-Focused Care: We prioritize patient comfort, safety, and clear communication throughout the testing process.
• Quality Diagnostic Services: Lahore PCR Lab adheres to strict international quality control standards to ensure clinical accuracy.
• Professional Reporting: Comprehensive, easy-to-read reports that provide clear quantitative and qualitative data for clinicians.
• Modern Diagnostic Approach: Utilizing advanced immunological platforms, including line immunoassays and ELISA, for reliable antibody detection.
• Comfortable Environment: Our diagnostic center in Lahore offers a clean, hygienic, and welcoming environment for all patients.
• Convenient Location: Easily accessible location in Lahore, Pakistan, offering flexible hours for sample collection.
• Commitment to Accurate Diagnosis: Dedicated to providing precise diagnostic insights that empower physicians to make informed treatment decisions.